POSTERS Table (abstract P0840): Demographics of all HCV genotype 3 and 4 infection patients who started treatment Variable HCV genotype 3 HCV genotype 4 Treatment regimen SOF/PEG/RBV SOF/RBV Total SOF/PEG/RBV SOF/RBV SOF/SMV SOF/SMV/RBV Total Subjects 18 184 202 23 12 6 6 47 Male, n (%) 12 (67) 114 (62) 126 (62) 18 (78) 11 (92) 4 (67) 4 (67) 37 (79) Mean age (yrs) 51 55 55 54 59 59 57 56 White race, n (%) 14 (78) 147 (80) 161 (80) 10 (44) 6 (50) 2 (33) 3 (50) 21 (45) Treatment-experienced, n (%) 10 (56) 92 (50) 102 (50) 16 (70) 9 (75) 3 (50) 5 (83) 33 (70) Cirrhosis, n (%) 9 (50) 94 (51) 103 (51) 7 (30) 6 (50) 3 (50) 2 (33) 18 (38) Post-Liver transplant, n (%) 1 (6) 18 (10) 19 (9) 0 (0.0) 1 (8) 0 (0.0) (0.0) 1 (2) currently available, 22/38 (58%) and 5/5 (100%) of GT3 patients treated with SOF/RBV and SOF/RBV/PEG, respectively, achieved SVR4 and 14/16 (88%) and 4/4 (100%) of GT4 patients treated with SOF/PEG/RBV and SOF/SIMSMV±RBV, respectively, achieved SVR4. Complete efficacy data will be presented Conclusions: Preliminary safety and efficacy data from HCVT for patients with HCV genotype 3 and 4 infections suggests that sofosbuvir-containing treatment regimens are generally safe and well tolerated across a broad spectrum of patients and clinical practices. P0841 SUCCESSFUL COMMUNITY BASED TREATMENT OF HEPATITIS C IN PEOPLE WHO INJECT DRUGS A.J. Wade 1,2,3 , D. Macdonald 4 , J.S. Doyle 1,2,4 , A.J. Thompson 5 , S.K. Roberts 6,7 , M.E. Hellard 1,2,4 . 1 Centre for Population Health, Burnet Institute, 2 School of Public Health and Preventive Medicine, Monash University, Melbourne, 3 Infectious Diseases Department, Barwon Health, Geelong, 4 Department of Infectious Diseases, The Alfred, 5 Department of Gastroenterology, St Vincents Hospital, 6 Department of Gastroenterology, The Alfred, 7 Department of Medicine, Monash University, Melbourne, Australia E-mail: amanda.wade@me.com Background and Aims: Hepatitis C virus (HCV) treatment uptake is <2% in Australia. A new nurse led service was developed linking The Alfred Hospital to community clinics. The service aimed to increase access to care, targeting current and past people who inject drugs (PWID). A hepatology nurse and specialist physicians attended 3 primary care clinics; all offered opiate substitution therapy (OST). Assessment and management was nurse led. We aim to describe the success of this service engaging and treating PWID. Methods: A retrospective audit of the service was undertaken. All patients referred to the nurse from service inception in 2010 until 1/8/14 were determined by accessing clinic appointment scheduling. Data collected included; patient demographics, drug, alcohol and psychiatric history, results, treatment uptake and outcome and retention in care. Results: 462 patients were referred to the community hepatitis nurse service – 344 attended. 279 patients had chronic HCV infection, of these; 184 (66%) were male, 208 (75%) had a psychiatric diagnosis, 145 (52%) were on psychotropic medication, 257 (92%) were current or past PWID, 147 (53%) were on OST, and 99 (35%) reported current injecting drug use (IDU). 203 (73%) had a fibroscan. 15 (5%) patients had significant fibrosis (fibroscan score >9.0 kPa, or clinical evidence such as oesophageal varices). Fifty-five patients (20%) commenced HCV treatment; 47 had pegylated interferon (PEG) based regimens and 8 were enrolled in PEG-free directly acting antiviral (DAA) trials. Of the 55 patients who commenced treatment, 18 (33%) reported current IDU, 32 (58%) were on OST and 35 (64%) were on psychotropic medication. 14 patients are still undergoing treatment or are <3 months post treatment. Of the remaining 41 patients, 28 completed treatment, 6 ceased due to side effects, 6 fulfilled treatment futility criteria and 1 was lost to follow up. Of the 28 patients who completed therapy, 23 (56%) had a sustained virologic response (SVR). Factors associated with treatment uptake included OST and being on psychotropic medication. Of the 256 patients with chronic HCV who have not had an SVR, 95 (37%) remain engaged in care. Conclusions: This community based program successfully provided care and interferon based treatment to a significant number of PWID, with an SVR rate comparable to patients treated in tertiary institutions. With the advent of DAAs it highlights the benefits of community based HCV services in managing PWID, a group with a high prevalence of HCV infection. P0842 MALACHITE-I: PHASE 3B TRIAL OF OMBITASVIR/PARITAPREVIR/R AND DASABUVIR +/− RIBAVIRIN OR TELAPREVIR + PEGINTERFERON/RIBAVIRIN IN TREATMENT-NA ¨ IVE ADULTS WITH HCV GENOTYPE 1 B. Conway 1 , E. Janczewska 2 , Y. Luo 3 , M. Curescu 4 , S. Greenbloom 5 , A. Streinu-Cercel 6,7 , F.A. Caruntu 6 , W. Ghesquiere 8 , B. Knysz 9 , W. Mazur 10 , F. Fuster 11 , A. Motoc 12 , A. Soza 13 , V. Arama 6,7 , O. Dalgard 14 , D. Sullivan 3 , X. Liu 3 , T. Podsadecki 3 . 1 Vancouver ID Research and Care Centre, Vancouver, Canada; 2 ID Clinic, Mysłowice, Poland; 3 AbbVie Inc., North Chicago, United States; 4 Life Search SRL, Timisoara, Romania; 5 Toronto Digestive Disease Associates, Toronto, Canada; 6 National Institute for Infectious Diseases “Prof. Dr. Matei Bals”, 7 Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; 8 Island Health Authority, Section of Infectious Diseases, Victoria, Canada; 9 Wrocław Medical University, Wrocław, 10 Clinical Department of Infectious Disease, Medical University of Silesia, Katowice, Poland; 11 Instituto Oncologico, Vi˜na del Mar, Chile; 12 Hospital of Infectious Diseases Dr. Victor Babes, Bucharest, Romania; 13 Department of Gastroenterology, Pontificia Universidad Catolica de Chile, Santiago, Chile; 14 Akershus University Hospital, Lorenskog, Norway E-mail: christine.ratajczak@abbvie.com Background and Aims: In phase 3 trials, regimens of co- formulated ombitasvir/paritaprevir/r (paritaprevir [formerly ABT- 450] identified by AbbVie and Enanta, co-dosed with ritonavir [r]) and dasabuvir +/− ribavirin (3D±RBV) demonstrated high efficacy rates and low rates of drug discontinuation due to adverse events (AEs) in patients with chronic HCV genotype (GT) 1 infection. Telaprevir (TPV) plus peginterferon (pegIFN)/RBV remains the standard of care for chronic HCV GT1 infection in many regions. However, this regimen is associated with long treatment duration, suboptimal efficacy, and treatment-limiting AEs related to pegIFN/RBV and exacerbated by TPV-associated rash and anemia. MALACHITE-I is the first multicenter trial to directly compare efficacy and safety of an all-oral direct-acting antiviral regimen (3D±RBV) and TPV+pegIFN/RBV in treatment-naive HCV GT1-infected pts without cirrhosis. Methods: This multicenter, open-label trial included 311 HCV GT1-infected treatment-naive patients without cirrhosis. Patients received 3D+RBV for 12 weeks, 3D for 12 weeks, or TPV+pegIFN/RBV for 12 weeks and pegIFN/RBV for an additional 12–36 weeks (total treatment duration of 24–48 weeks). Patients with GT1a infection Journal of Hepatology 2015 vol. 62 | S263–S864 S653